Millennium Management Portfolio holdings
Millennium Management, founded in 1989 by Israel (Izzy) Englander and Ronald Shear and headquartered in New York City, is a global multi-strategy hedge fund managing over $71 billion in assets as of late 2024, employing a decentralized model with over 300 independent trading teams. Operating across equities, fixed income, commodities, currencies, and derivatives, the firm uses a mix of quantitative and fundamental strategies, providing its portfolio managers with capital, infrastructure, and autonomy to pursue diverse investment approaches while enforcing strict risk management. With more than 5,400 employees across offices in London, Hong Kong, Singapore, and beyond, Millennium has evolved from its initial $35 million seed capital—partly from the Belzberg family—into a titan of the hedge fund world, known for its ability to attract top talent and deliver consistent returns. Under Englander’s leadership as chairman and CEO, the firm remains a low-profile yet highly influential force in global finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$643M |
| 2 |
AT&T
T
|
+$311M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$306M |
| 4 |
Microsoft
MSFT
|
+$292M |
| 5 |
Ametek
AME
|
+$215M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$887M |
| 2 |
Apple
AAPL
|
+$694M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$616M |
| 4 |
Amazon
AMZN
|
+$596M |
| 5 |
Linde
LIN
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 7.39% |
| 2 | Financials | 6.67% |
| 3 | Healthcare | 6.18% |
| 4 | Industrials | 4.97% |
| 5 | Consumer Discretionary | 4.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HOFV
4001
DELISTED
Hall of Fame Resort & Entertainment Co
HOFV
| $1.81M | ﹤0.01% |
+30,994
| New | +$2.08M |
|
4002
Immunovant
IMVT
$8.08B
| $1.81M | ﹤0.01% |
207,926
-288,497
| -58% | -$2.6M |
|
4003
CALL
Cardinal Health
CAH
$54.7B
| $1.8M | ﹤0.01% |
36,500
-139,500
| -79% | -$7.57M |
|
4004
CorVel
CRVL
$3.01B
| $1.8M | ﹤0.01% |
29,076
+3,789
| +15% | +$197K |
|
4005
Sera Prognostics
SERA
$75.6M
| $1.8M | ﹤0.01% |
+162,245
| New | +$1.68M |
|
|
SGMO
4006
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $1.8M | ﹤0.01% |
199,619
+41,768
| +26% | +$413K |
|
|
ATMR.U
4007
DELISTED
Altimar Acquisition Corp II Units
ATMR.U
| $1.8M | ﹤0.01% |
181,000
-1,058,617
| -85% | -$10.7M |
|
|
EVBN
4008
DELISTED
Evans Bancorp Inc
EVBN
| $1.79M | ﹤0.01% |
46,865
-27,041
| -37% | -$1.04M |
|
|
JNCE
4009
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $1.79M | ﹤0.01% |
241,225
-217,091
| -47% | -$1.34M |
|
|
FIV
4010
DELISTED
First Trust Senior Floating Rate 2022 Target Term Fund Common Shares of Beneficial Interest
FIV
| $1.79M | ﹤0.01% |
185,619
| – | – |
|
4011
Alaunos Therapeutics
TCRT
$4.64M
| $1.78M | ﹤0.01% |
6,539
+4,078
| +166% | +$1.25M |
|
4012
Green Dot
GDOT
$748M
| $1.78M | ﹤0.01% |
35,422
-4,149
| -10% | -$200K |
|
4013
OneWater Marine
ONEW
$213M
| $1.78M | ﹤0.01% |
44,349
+1,752
| +4% | +$73.5K |
|
4014
Caribou Biosciences
CRBU
$156M
| $1.78M | ﹤0.01% |
+74,674
| New | +$1.83M |
|
4015
Sturm, Ruger & Co
RGR
$625M
| $1.78M | ﹤0.01% |
24,150
+20,100
| +496% | +$1.56M |
|
|
EVLO
4016
PUT
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $1.78M | ﹤0.01% |
+12,645
| New | +$2.51M |
|
|
BOAS
4017
DELISTED
BOA Acquisition Corp.
BOAS
| $1.78M | ﹤0.01% |
183,357
-465,900
| -72% | -$4.51M |
|
|
ONT
4018
Onterris Inc
ONT
$826M
| $1.78M | ﹤0.01% |
28,811
+11,885
| +70% | +$622K |
|
4019
CALL
State Street
STT
$50.9B
| $1.78M | ﹤0.01% |
+21,000
| New | +$1.83M |
|
|
SY
4020
So-Young International
SY
$200M
| $1.78M | ﹤0.01% |
417,490
-261,094
| -38% | -$1.7M |
|
4021
Marathon Digital Holdings
MARA
$4.48B
| $1.77M | ﹤0.01% |
+56,164
| New | +$1.83M |
|
|
PMBC
4022
DELISTED
Pacific Mercantile Bancorp
PMBC
| $1.77M | ﹤0.01% |
192,412
+48,645
| +34% | +$421K |
|
4023
CALL
SL Green Realty
SLG
$3.97B
| $1.77M | ﹤0.01% |
+25,000
| New | +$1.83M |
|
4024
CALL
Iron Mountain
IRM
$37.3B
| $1.77M | ﹤0.01% |
+40,700
| New | +$1.83M |
|
4025
Nautilus Biotechnolgy
NAUT
$125M
| $1.77M | ﹤0.01% |
287,649
+249,548
| +655% | +$1.99M |
|
Similar funds
Millennium Management's Q3 2021 Portfolio in Review
As of Q3 2021, Millennium Management held 7,698 positions worth $167B, up 2.3% from $163B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Millennium Management deployed $8.65B of net new capital in Q3 2021, opening 1,244 new positions and adding to 2,720 existing holdings. Its largest new stake was Sight Sciences: 1,577,092 shares worth $35.8M.
By sector, the portfolio is most concentrated in Technology at 7.4% of assets, down from 7.8% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Apple, an estimated $694M trimmed.
- Millennium Management's largest Q3 2021 buy was Sight Sciences: 1,577,092 shares worth $35.8M.
- Millennium Management added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $643M increase.
- Millennium Management's biggest Q3 2021 reduction was Apple, cutting an estimated $694M.
- Millennium Management fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $887M.
- Millennium Management's ten largest holdings make up 18% of its $167B portfolio in Q3 2021.
- Millennium Management opened 1,244 new positions and closed 981 in Q3 2021.
- Millennium Management's portfolio value rose 2.3% quarter-over-quarter to $167B.
Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.